Surmounting the Insurmountable: Obstacles in Drug Discovery and Development - Real World Case Studies
Monday April 23, 2018
Co-sponsored by the Division for Behavioral Pharmacology (BEH)
Co-sponsored by the Division for Cancer Pharmacology (DCP)
Co-sponsored by the Division for Drug Discovery and Development (DDD)
Co-sponsored by the Division for Drug Metabolism and Disposition (DMDD)
Co-sponsored by the Division for Translational and Clinical Pharmacology (TCP)
University of Michigan
During the drug discovery and development process in the real world, expert scientists frequently encounter an unexpected obstacle that seems insurmountable. Serious issues with efficacy, toxicity, and pharmacokinetics may unexpectedly threaten the successful development of the whole project. How do experienced scientists deal with such issues? Critical thinking and problem solving are essential for success. This session features recognized experts in drug discovery and development and their fascinating and challenging stories. What went fatally wrong with a particular drug? How was the problem solved?
Challenges and Solutions in the Approval of Austedo, the First Deuterium-Substituted Small Molecule
- Prana Biotech
Discovery and Development Challenges of Dasatinib for the Treatment of Chronic Myelogenous Leukemia and Beyond
- Angex Pharmaceutical Inc.
Modeling and Simulation that Resulted in the Progression of Evolucumab
Fasiglifam (TAK-875) Alters Bile Acid Homeostasis in Rats and Dogs: A Potential Cause of Drug Induced Liver Injury
- Takeda Pharmaceuticals International Co.
- University of Michigan